Literature DB >> 24000319

Reversibility of Liver Fibrosis and Inactivation of Fibrogenic Myofibroblasts.

Xiao Liu1, Jun Xu, David A Brenner, Tatiana Kisseleva.   

Abstract

Many studies have demonstrated that hepatic fibrosis is reversible. Regression of liver fibrosis is associated with resorption of fibrous scar and disappearance of collagen producing myofibroblasts. The fate of these myofibroblasts has been recently revealed: Some myofibroblasts undergo senescence and apoptose during reversal of fibrosis, while other myofibroblasts revert to a quiescent-like phenotype. Inactivation of myofibroblasts is a newly described phenomenon1 which now requires mechanistic investigation. Understanding of the mechanism of HSC inactivation upon cessation of fibrogenic stimuli may identify new approaches to revert already existing aHSCs/myofibroblasts into a quiescent-like state. This review summarizes the research on the inactivation of hepatic myofibroblasts.

Entities:  

Keywords:  Collagen; HSCs; Hepatic fibrosis; Hepatic stellate cells; Inactivation of myofibroblasts; Pathobiology; Reversibility of liver fibrosis

Year:  2013        PMID: 24000319      PMCID: PMC3757252          DOI: 10.1007/s40139-013-0018-7

Source DB:  PubMed          Journal:  Curr Pathobiol Rep        ISSN: 2167-485X


  36 in total

Review 1.  The myofibroblast in pulmonary fibrosis.

Authors:  Sem H Phan
Journal:  Chest       Date:  2002-12       Impact factor: 9.410

Review 2.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

3.  Analysis of bacteriophage P1 immunity by using lambda-P1 recombinants constructed in vitro.

Authors:  N Sternberg; S Austin; D Hamilton; M Yarmolinsky
Journal:  Proc Natl Acad Sci U S A       Date:  1978-11       Impact factor: 11.205

Review 4.  Hepatic stellate cells and the reversal of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  J Gastroenterol Hepatol       Date:  2006-10       Impact factor: 4.029

5.  Regression of liver fibrosis after biliary drainage in patients with chronic pancreatitis and stenosis of the common bile duct.

Authors:  P Hammel; A Couvelard; D O'Toole; A Ratouis; A Sauvanet; J F Fléjou; C Degott; J Belghiti; P Bernades; D Valla; P Ruszniewski; P Lévy
Journal:  N Engl J Med       Date:  2001-02-08       Impact factor: 91.245

6.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.

Authors:  J P Iredale; R C Benyon; J Pickering; M McCullen; M Northrop; S Pawley; C Hovell; M J Arthur
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

Review 7.  Fibrocytes in lung disease.

Authors:  Brigitte N Gomperts; Robert M Strieter
Journal:  J Leukoc Biol       Date:  2007-06-05       Impact factor: 4.962

8.  Decreased fibrosis during corticosteroid therapy of autoimmune hepatitis.

Authors:  Albert J Czaja; Herschel A Carpenter
Journal:  J Hepatol       Date:  2004-04       Impact factor: 25.083

9.  Scar-associated macrophages are a major source of hepatic matrix metalloproteinase-13 and facilitate the resolution of murine hepatic fibrosis.

Authors:  Jonathan A Fallowfield; Masashi Mizuno; Timothy J Kendall; Christothea M Constandinou; R Christopher Benyon; Jeremy S Duffield; John P Iredale
Journal:  J Immunol       Date:  2007-04-15       Impact factor: 5.422

10.  Inactivation of myofibroblasts during regression of liver fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

View more
  37 in total

1.  Comprehensive characterization of hepatocyte-derived extracellular vesicles identifies direct miRNA-based regulation of hepatic stellate cells and DAMP-based hepatic macrophage IL-1β and IL-17 upregulation in alcoholic hepatitis mice.

Authors:  Akiko Eguchi; Rui Yan; Stephanie Q Pan; Raymond Wu; Jihoon Kim; Yibu Chen; Charles Ansong; Richard D Smith; Mina Tempaku; Lucila Ohno-Machado; Yoshiyuki Takei; Ariel E Feldstein; Hidekazu Tsukamoto
Journal:  J Mol Med (Berl)       Date:  2020-06-18       Impact factor: 4.599

2.  Analysis of Pathological Activities of CCN Proteins in Fibrotic Diseases: Liver Fibrosis.

Authors:  Li Chen; David R Brigstock
Journal:  Methods Mol Biol       Date:  2017

3.  Inhibition of acidic sphingomyelinase reduces established hepatic fibrosis in mice.

Authors:  Ralph C Quillin; Gregory C Wilson; Hiroyuki Nojima; Christopher M Freeman; Jiang Wang; Rebecca M Schuster; John A Blanchard; Michael J Edwards; Chandrashekhar R Gandhi; Erich Gulbins; Alex B Lentsch
Journal:  Hepatol Res       Date:  2014-06-04       Impact factor: 4.288

4.  Reversibility of liver fibrosis.

Authors:  David A Brenner
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-11

Review 5.  ABO-compatible liver allograft antibody-mediated rejection: an update.

Authors:  Anthony J Demetris; Adriana Zeevi; Jacqueline G O'Leary
Journal:  Curr Opin Organ Transplant       Date:  2015-06       Impact factor: 2.640

Review 6.  Microenvironment and tumor cells: two targets for new molecular therapies of hepatocellular carcinoma.

Authors:  Laura Amicone; Alessandra Marchetti
Journal:  Transl Gastroenterol Hepatol       Date:  2018-05-02

7.  FIB-4 stage of liver fibrosis predicts incident heart failure among HIV-infected and uninfected patients.

Authors:  Kaku A So-Armah; Joseph K Lim; Vincent Lo Re; Janet P Tate; Chung-Chou H Chang; Adeel A Butt; Cynthia L Gibert; David Rimland; Vincent C Marconi; Matthew B Goetz; Maria C Rodriguez-Barradas; Matthew J Budoff; Hilary A Tindle; Jeffrey H Samet; Amy C Justice; Matthew S Freiberg
Journal:  Hepatology       Date:  2017-08-30       Impact factor: 17.425

Review 8.  Bone marrow derived stem cells for the treatment of end-stage liver disease.

Authors:  Cristina Margini; Ranka Vukotic; Lucia Brodosi; Mauro Bernardi; Pietro Andreone
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 9.  Mechanisms of Lung Fibrosis Resolution.

Authors:  Stephan W Glasser; James S Hagood; Simon Wong; Carmen A Taype; Satish K Madala; William D Hardie
Journal:  Am J Pathol       Date:  2016-03-25       Impact factor: 4.307

Review 10.  New Developments on the Treatment of Liver Fibrosis.

Authors:  Yukinori Koyama; Jun Xu; Xiao Liu; David A Brenner
Journal:  Dig Dis       Date:  2016-06-22       Impact factor: 2.404

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.